Increased Myozyme Dosing May Help With Classic Infantile Pompe

Increased Myozyme Dosing May Help With Classic Infantile Pompe

315435

Increased Myozyme Dosing May Help With Classic Infantile Pompe

Patients with classic infantile-onset Pompe disease could benefit from increased dosing of Myozyme (alglucosidase alfa), an enzyme replacement therapy (ERT) marketed as Lumizyme in the U.S., according to a real-world European study. Benefits were seen in improved survival and ability to walk. “On the basis of our results, we suggest that the current standard recommended dosage of alglucosidase alfa in patients with classic infantile Pompe disease should be reconsidered,” the scientists wrote. The study, “Effect…

You must be logged in to read/download the full post.